Business description: Hologic, Inc.

Hologic, Inc. is the world leader in the design, manufacturing and marketing of diagnostic products, medical imaging systems and surgical products dedicated to women's health. Net sales break down by area of application as follows:

- molecular diagnostics (46.7%): rapid diagnostic tests for human diseases detection (sexually transmitted infections, respiratory diseases, viral diseases, infectious diseases, cancers of the cervix and prostate, etc.) and fetal fibronectin;

- breast health (35.5%): digital mammography and breast biopsy solutions and systems;

- gynecological surgery (15%): endometrial ablation devices, minimally invasive intervention systems for the hysteroscopic elimination of targeted intrauterine diseases (including fibroids and polyps). The group also offers fluid management systems for use in hysteroscopic procedures;

- bone health (2.8%): bone imaging systems, bone sonometers and osteodensitometers for bone structure and density, and osteoporotic fractures risk assessment.

Net sales break down by source of revenue between sales of products (81.4%) and services (18.6%).

Net sales are distributed geographically as follows: the United States (75.9%), Europe (12.9%), Asia/Pacific (6.3%) and other (4.9%).

Number of employees: 6,990

Sales by Activity: Hologic, Inc.

Fiscal Period: September20192020202120222023

Diagnostics

1.21B 2.1B 3.7B 3.02B 1.88B

Breast Health

1.31B 1.15B 1.35B 1.23B 1.43B

GYN Surgical

437M 376M 488M 523M 604M

Skeletal Health

94.8M 81M 96.9M 93.6M 113M

Medical Aesthetics

316M 65.3M - - -
See all business segments

Geographical breakdown of sales: Hologic, Inc.

Fiscal Period: September20192020202120222023

United States

2.54B 2.86B 3.9B 3.47B 3.06B

Europe

396M 570M 1.2B 888M 520M

Asia-Pacific

286M 227M 365M 360M 256M

All Others

149M 117M 163M 147M 196M
See all geographic segments

Managers: Hologic, Inc.

Director TitleAgeSince
Chief Executive Officer 60 06/12/2013
Director of Finance/CFO 54 31/07/2018
Chief Operating Officer 44 31/12/2023
Chief Tech/Sci/R&D Officer - 30/06/2021
Investor Relations Contact - 31/12/2021
See HOLOGIC, INC. governance

Members of the board: Hologic, Inc.

Manager TitleAgeSince
Director/Board Member 70 21/10/2007
Director/Board Member 53 31/10/2011
Director/Board Member 73 05/05/2013
Chairman 60 15/06/2015
Director/Board Member 69 14/05/2017
Director/Board Member 63 30/11/2016
Director/Board Member 61 20/11/2018
Director/Board Member 59 01/01/2023
Director/Board Member 46 19/09/2023
Director/Board Member 64 05/12/2024
Composition of the Board of Directors

Shareholders: Hologic, Inc.

NameEquities%Valuation
Vanguard Fiduciary Trust Co.
11.88 %
26,952,364 11.88 % 2 143 M $
T. Rowe Price Investment Management, Inc.
9.755 %
22,137,236 9.755 % 1 760 M $
BlackRock Advisors LLC
6.978 %
15,834,930 6.978 % 1 259 M $
Eaton Vance Management
4.792 %
10,875,674 4.792 % 865 M $
10,409,327 4.587 % 828 M $
List of HOLOGIC, INC. shareholders

Company details: Hologic, Inc.

Hologic, Inc.

250 Campus Drive

01752, Marlborough

+508 263 2900

http://www.hologic.com
address Hologic, Inc.(HOLX)

Group companies: Hologic, Inc.

NameCategory and Sector
Medical Specialties
Medical Distributors
See all subsidiaries

Other Advanced Medical Equipment & Technology

Add to a list
Change 5d. change 1-year change 3-years change Capi. ($)
-1.69%-1.74%+9.97%+1.04%17.44B
-0.28%+1.04%+7.95%-16.83%205B
+1.02%-1.15%+72.34%+57.58%192B
+0.45%-0.36%+6.35%-25.86%169B
+0.40%-0.31%+63.88%+119.97%133B
+1.08%+4.52%+3.48%-19.47%62.94B
-0.26%+1.06%-11.93%-29.22%43.85B
+0.57%-0.53%+4.98%-39.42%43.29B
-0.52%+0.71%+9.48%-9.64%40.48B
+0.47%-0.31%+16.34% - 37.63B
Average +0.12%+0.24%+18.28%+4.24% 94.44B
Weighted average by Cap. +0.33%-0.14%+27.68%+16.07%
See all sector performances
Trading Rating
Investor Rating
ESG Refinitiv
B+
surperformance-ratings-light-chart HOLOGIC-INCMore Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
75.53USD
Average target price
87.19USD
Spread / Average Target
+15.44%
Consensus

Quarterly revenue - Rate of surprise